B3GAT2: A Potential Drug Target for Neurological Disorders (G135152)

Target Name: B3GAT2

NCBI ID: G135152

B3GAT2

B3GAT2: A Potential Drug Target for Neurological Disorders

B3GAT2 (B3GA2_HUMAN) is a protein that is expressed in human tissues and has been identified as a potential drug target or biomarker. The protein is a key component of the nervous system and is involved in the development and maintenance of neuronal connections.

Research has shown that B3GAT2 plays a role in the regulation of synaptic plasticity, which is the ability of the nervous system to change and adapt in response to experience. B3GAT2 has been shown to promote the formation of new neurons and to modulate the activity of existing neurons.

Additionally, B3GAT2 has been shown to be involved in the regulation of neurotransmitter release and the modulation of pain perception. This suggests that it may be a useful target for the development of new treatments for a variety of neurological and psychiatric disorders.

Despite the potential benefits of B3GAT2 as a drug target, further research is needed to fully understand its role in the nervous system and its potential as a therapeutic agent.

In conclusion, B3GAT2 is a protein that has the potential to be a drug target or biomarker for a variety of neurological and psychiatric disorders. Further research is needed to fully understand its role in the nervous system and its potential as a therapeutic agent.

Protein Name: Beta-1,3-glucuronyltransferase 2

Functions: Involved in the biosynthesis of L2/HNK-1 carbohydrate epitope on both glycolipids and glycoproteins

The "B3GAT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about B3GAT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets